Human lives
drive our discovery
of microbiome therapeutics

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more


We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.

Learn more

Recent news

Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

October 12, 2021

Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors

October 05, 2021

Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer

September 08, 2021

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more